Yingke Capital

What Yingke Capital does

Yingke Capital is a research-driven private equity and venture capital firm founded in 2010, headquartered in Shanghai with operations across China and registered in Fujian Province (legal name: Yingke Innovation Asset Management Co., Ltd.). The firm manages approximately 500 billion RMB (RMB 50 billion) in assets under management, with over 90% of entrusted capital sourced from institutional investors including banks (wealth management), insurance funds, central state-owned enterprises, and listed companies. It operates two principal revenue streams: recurring management fees on fund AUM (subscription-style, annual billing) and carried interest from successful exits, supported by a near-100-person professional research team organized around three core tracks: Life Sciences (biomedicine, vaccines, gene therapy, rare disease, medical devices), Dual Carbon Technology (EVs, wind/solar, energy storage, hydrogen), and Hard Core Technology (semiconductors, advanced manufacturing, new materials).

The firm's go-to-market is institution-led direct fundraising from LPs combined with co-establishment of government-guided industry funds across Shandong, Anhui, Jiangsu, Zhejiang, and Fujian. Its investment methodology emphasizes deep industry research ("research-driven investment") rather than broad spray-and-pray, with proprietary sector coverage teams including approximately 30 PhDs in biomedicine. Yingke has deployed capital into 300+ portfolio companies (60+ in biomedicine alone), with notable exits including 15 IPOs in 2020 across ChiNext, STAR Board, main board, and HKEX. Strategic LP/ecosystem relationships include Tigermed (China's largest clinical CRO), Pien Tze Huang, and major SOE banks (Agricultural Bank of China, CITIC Bank, Industrial Bank, Hengfeng Bank). Its portfolio support platform, the "Golden Sycamore Industry Landing Plan," provides operating support beyond capital deployment. The firm controls two wholly-owned subsidiaries: Ruiying Asset (strategic holdings, including control of Aolian Electronics 300585.SZ) and Chitai Asset (quantitative investment strategies).

Name

Yingke Capital

Legal name

盈科创新资产管理有限公司

Website

http://www.yingkepe.com/

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Yingke Capital is a China-focused research-driven private equity and venture capital firm managing approximately RMB 50 billion in AUM, investing across life sciences, dual-carbon technology, and hard-tech sectors from institutional LP capital.

Ownership category

akta.pro rank

Product category

Private Equity & Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Private equity investment
• Venture capital management
• Biomedical investment
• Technology sector investment
• Institutional asset management

Headquarters

HQ city

Fuzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. 基金管理费收入: 向LP收取的基金管理费，通常为管理资产规模的一定比例
2. 附带权益(Carried Interest): 从投资项目的利润中提取分成，作为基金业绩的主要回报来源

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Yingke Capital is a research-driven professional private equity investment institution founded in 2010, managing approximately 500 billion RMB in assets with over 90% sourced from institutional investors. The firm focuses on three core investment tracks — Life Sciences (biotech, vaccines, gene therapy, medical devices), Dual Carbon Technology (new energy, EVs, hydrogen, storage), and Hard Core Technology (semiconductors, advanced manufacturing, new materials) — providing equity capital and strategic support to portfolio companies across pre-IPO, strategic, and growth stages.

Product overview

Yingke Capital is a venture capital and private equity investment firm, not a technology product company. The company operates as a research-driven investment institution focused on three core sectors: Life Sciences (including biotech, vaccines, medical devices), Dual Carbon Technology (new energy, EVs, renewables), and Hard Core Technology (semiconductors, advanced manufacturing). The firm's main offering is investment management services, providing capital and strategic support to portfolio companies through its 'Golden Sycamore Industry Landing Plan' (金梧桐产业落地计划). As an investment institution, it does not offer software products, platforms, or API services in the traditional SaaS sense.

Differentiator

Problem solved

Functional benefit

Brands

• 金梧桐产业落地计划 (Golden梧桐 Industrial Landing Plan): 盈科资本的产业落地计划，旨在整合优势资源，促进企业新建产能落地，助力企业高质量成长
• 盈科Family

Products and services

• China Core Asset Strategic Allocation Fund (中国核心资产战略配置基金) A 10 billion RMB investment fund focused on core technology and biomedical sectors, providing equity capital and strategic support to portfolio companies. Targets institutional LPs and serves as Yingke's flagship strategic allocation vehicle.
• Biomedical Industry Funds (生物医药专项基金) Two specialized funds totaling 1 billion RMB dedicated to biomedical industry investments, including innovative drugs, vaccines, gene therapy, and rare disease treatment. Focused on driving biomedical project industrial landing in Hefei with expected total investment of approximately 8 billion RMB.
• Pianzi Huang Yingke Health Industry Fund (片仔癀盈科健康产业基金) A 1 billion RMB industry fund co-established with listed pharmaceutical company Pianzi Huang, investing in traditional Chinese medicine, biomedicine, medical devices, and services sectors. Targets high-quality enterprises across the broader healthcare industry chain.
• Golden Sycamore Industry Landing Plan (金梧桐产业落地计划) A structured value-added service program under Yingke Capital that integrates superior resources to help portfolio enterprises establish new production capacity, supporting high-quality growth and full-cycle empowerment of invested companies.

Quantifiable outcome

• 2020年录得15个IPO项目
• +3 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and major.

• 片仔癀coreStrategic or Co-development Partner盈科资本与上市龙头药企片仔癀携手，合作设立了总规模为10亿元的片仔癀盈科健康产业基金，投资中医药产业、生物医药、医疗器械及服务等优质企业
• 中国农业银行majorStrategic or Co-development Partner盈科资本签约成为农业银行股权生态圈核心伙伴，深化综合金融合作
• 中信银行majorStrategic or Co-development Partner盈科资本与中信银行签署战略合作协议，深化综合金融合作
• 兴业证券majorStrategic or Co-development Partner盈科资本与兴业证券签署战略合作协议
• 浦发银行majorStrategic or Co-development Partner盈科资本与浦发银行建立合作关系，共同服务实体企业
• 恒丰银行majorStrategic or Co-development Partner盈科资本与恒丰银行战略合作共建3支百亿基金

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• HongShan (formerly Sequoia China): One of China's largest venture capital and growth equity firms, spun off from Sequoia Capital in 2023. Directly comparable as a sector-focused VC/PE investing across technology, healthcare, and consumer with comparable AUM scale and IPO exit track record.
• Hillhouse Capital: Asia-focused investment firm of significant scale managing public and private equity across healthcare, consumer, and technology. Comparable as a research-driven institution with similar institutional LP base and sector specialization.
• IDG Capital: One of China's earliest VC firms investing across technology, healthcare, and advanced manufacturing. Comparable scale, multi-stage approach, and similar sector exposure to hard tech and biomedical investments.
• Legend Capital: Chinese growth equity firm backed by Lenovo Holdings, focused on technology and healthcare investments with comparable AUM and institutional LP base. Direct competitor in biomedical and hard-tech verticals.
• MatrixPartners China: Leading early-to-growth stage Chinese VC firm investing across technology, healthcare, and consumer. Comparable sector-focused approach with strong IPO exit track record in China.
• CDH Investments: Major Chinese alternative asset manager with focus on private equity across healthcare, consumer, and industrial sectors. Comparable scale and institutional LP base with overlapping biomedical investment strategy.
• Boyu Capital: Asia-focused alternative investment firm with substantial AUM, investing across growth equity and healthcare. Comparable as a large-scale Chinese/Asian PE firm with sector-focused strategy.
• CITIC Capital: Chinese alternative asset manager backed by CITIC Group, with focus on private equity, real estate, and special situations. Comparable institutional LP backing and multi-sector investment approach.
• Primavera Capital: China-focused private equity firm investing across technology, healthcare, and consumer with comparable institutional LP base. Direct competitor in growth-stage Chinese investments.

Emerging players

• GL Ventures (Hillhouse): Growth equity arm of Hillhouse Capital focused on later-stage investments in China. Comparable in growth-stage Chinese equity investing, particularly in tech and healthcare verticals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments102 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yingke Capital